Literature DB >> 2463123

Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation.

T E Mollnes1, P Garred, G Bergseth.   

Abstract

The effects of time, temperature, ethylene-diamine-tetra-acetic acid (EDTA), citrate and heparin on in vitro complement activation were examined in enzyme immuno assays (EIA) for detection of C3 activation products and the terminal complement complex (TCC). In vitro complement activation occurred during coagulation since baseline concentrations of activation products were considerably higher in serum than in plasma. EDTA was more efficient than citrate and heparin in inhibiting in vitro activation. Minimal activation was observed in all preparations when samples were kept at 4 degrees C for up to ten days, whereas a very rapid increase in activation products occurred even in EDTA plasma when the temperature was elevated. Based on the data obtained, guidelines for the collection and preservation of samples to be examined for complement activation are given.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2463123      PMCID: PMC1541764     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

1.  Activation of the third component of complement (C3) detected by a monoclonal anti-C3'g' neoantigen antibody in a one-step enzyme immunoassay.

Authors:  T E Mollnes; P J Lachmann
Journal:  J Immunol Methods       Date:  1987-08-03       Impact factor: 2.303

2.  Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c.

Authors:  P Garred; T E Mollnes; T Lea; E Fischer
Journal:  Scand J Immunol       Date:  1988-03       Impact factor: 3.487

3.  An efficient one-step method for isolating immune complexes from whole serum using a monoclonal anti-C3g affinity immunosorbent.

Authors:  D J Samuel; P L Amlot; P Shepherd; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

4.  Early- and late-phase activation of complement evaluated by plasma levels of C3d,g and the terminal complement complex.

Authors:  T E Mollnes
Journal:  Complement       Date:  1985

5.  Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism.

Authors:  R J Ziccardi
Journal:  J Immunol       Date:  1982-06       Impact factor: 5.422

6.  Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex.

Authors:  T E Mollnes; T Lea; S S Frøland; M Harboe
Journal:  Scand J Immunol       Date:  1985-08       Impact factor: 3.487

7.  Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3.

Authors:  P Garred; T E Mollnes; T Lea
Journal:  Scand J Immunol       Date:  1988-03       Impact factor: 3.487

8.  Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase.

Authors:  M D Kazatchkine; D T Fearon; D D Metcalfe; R D Rosenberg; K F Austen
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

9.  Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies.

Authors:  P J Lachmann; M K Pangburn; R G Oldroyd
Journal:  J Exp Med       Date:  1982-07-01       Impact factor: 14.307

10.  Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin.

Authors:  J M Weiler; R W Yurt; D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1978-02-01       Impact factor: 14.307

View more
  57 in total

Review 1.  Modern complement analysis.

Authors:  Michael Kirschfink; Tom E Mollnes
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

2.  A quantitative lateral flow assay to detect complement activation in blood.

Authors:  Elizabeth C Schramm; Nick R Staten; Zhouning Zhang; Samuel S Bruce; Christopher Kellner; John P Atkinson; Vasileios C Kyttaris; George C Tsokos; Michelle Petri; E Sander Connolly; Paul K Olson
Journal:  Anal Biochem       Date:  2015-02-04       Impact factor: 3.365

3.  Activation of complement during apheresis.

Authors:  G Hetland; T E Mollnes; P Garred
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

Review 4.  Interactions between coagulation and complement--their role in inflammation.

Authors:  Katerina Oikonomopoulou; Daniel Ricklin; Peter A Ward; John D Lambris
Journal:  Semin Immunopathol       Date:  2011-08-03       Impact factor: 9.623

5.  Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome.

Authors:  S Stöve; T Welte; T O Wagner; A Kola; A Klos; W Bautsch; J Köhl
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

6.  Quantification of Porcine Complement Activation Fragment C3a by a Neoepitope-Based Enzyme-Linked Immunosorbent Assay.

Authors:  Per H Nilsson; Kristin Pettersen; Martin Oppermann; Espen W Skjeflo; Hilde Fure; Dorte Christiansen; Tom Eirik Mollnes
Journal:  Methods Mol Biol       Date:  2021

7.  Plasma levels of soluble membrane attack complex are elevated despite viral suppression in HIV patients with poor immune reconstitution.

Authors:  T N Schein; T E Blackburn; S L Heath; S R Barnum
Journal:  Clin Exp Immunol       Date:  2019-09-08       Impact factor: 4.330

8.  The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Shuji Kanmura; Hirofumi Uto; Yuko Sato; Koutarou Kumagai; Fumisato Sasaki; Akihiro Moriuchi; Makoto Oketani; Akio Ido; Kenji Nagata; Katsuhiro Hayashi; Sherri O Stuver; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2009-12-09       Impact factor: 7.527

9.  Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies.

Authors:  Bernt Christian Hellerud; Audun Aase; Tove Karin Herstad; Lisbeth Meyer Naess; Lisa Høyem Kristiansen; Anne-Marie Siebke Trøseid; Morten Harboe; Knut Tore Lappegård; Petter Brandtzaeg; E Arne Høiby; Tom Eirik Mollnes
Journal:  Infect Immun       Date:  2009-11-23       Impact factor: 3.441

10.  Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease).

Authors:  J H Jansen; K Høgåsen; T E Mollnes
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.